Literature DB >> 12750232

Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system.

Denis E Corpet1, Fabrice Pierre.   

Abstract

The Apc(Min/+) mouse model and the azoxymethane (AOM) rat model are the main animal models used to study the effect of dietary agents on colorectal cancer. We reviewed recently the potency of chemopreventive agents in the AOM rat model (D. E. Corpet and S. Tache, Nutr. Cancer, 43: 1-21, 2002). Here we add the results of a systematic review of the effect of dietary and chemopreventive agents on the tumor yield in Min mice. The review is based on the results of 179 studies from 71 articles and is displayed also on the internet http://corpet.net/min.(2) We compared the efficacy of agents in the Min mouse model and the AOM rat model, and found that they were correlated (r = 0.66; P < 0.001), although some agents that afford strong protection in the AOM rat and the Min mouse small bowel increase the tumor yield in the large bowel of mutant mice. The agents included piroxicam, sulindac, celecoxib, difluoromethylornithine, and polyethylene glycol. The reason for this discrepancy is not known. We also compare the results of rodent studies with those of clinical intervention studies of polyp recurrence. We found that the effect of most of the agents tested was consistent across the animal and clinical models. Our point is thus: rodent models can provide guidance in the selection of prevention approaches to human colon cancer, in particular they suggest that polyethylene glycol, hesperidin, protease inhibitor, sphingomyelin, physical exercise, epidermal growth factor receptor kinase inhibitor, (+)-catechin, resveratrol, fish oil, curcumin, caffeate, and thiosulfonate are likely important preventive agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12750232      PMCID: PMC2797538     

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  116 in total

1.  Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network.

Authors:  D S Alberts; M E Martínez; D J Roe; J M Guillén-Rodríguez; J R Marshall; J B van Leeuwen; M E Reid; C Ritenbaugh; P A Vargas; A B Bhattacharyya; D L Earnest; R E Sampliner
Journal:  N Engl J Med       Date:  2000-04-20       Impact factor: 91.245

2.  Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group.

Authors:  A Schatzkin; E Lanza; D Corle; P Lance; F Iber; B Caan; M Shike; J Weissfeld; R Burt; M R Cooper; J W Kikendall; J Cahill
Journal:  N Engl J Med       Date:  2000-04-20       Impact factor: 91.245

3.  Treatment and survival study in the C57BL/6J-APC(Min)/+(Min) mouse with R-flurbiprofen.

Authors:  W J Wechter; E D Murray; D Kantoci; D D Quiggle; D D Leipold; K M Gibson; J D McCracken
Journal:  Life Sci       Date:  2000-01-14       Impact factor: 5.037

4.  Effects of p53 mutations on apoptosis in mouse intestinal and human colonic adenomas.

Authors:  A Fazeli; R G Steen; S L Dickinson; D Bautista; W F Dietrich; R T Bronson; R S Bresalier; E S Lander; J Costa; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

5.  Polyethylene-glycol suppresses colon cancer and causes dose-dependent regression of azoxymethane-induced aberrant crypt foci in rats.

Authors:  G Parnaud; S Taché; G Peiffer; D E Corpet
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

6.  Termination of piroxicam treatment and the occurrence of azoxymethane-induced colon cancer in rats.

Authors:  H Li; P M Kramer; R A Lubet; V E Steele; G J Kelloff; M A Pereira
Journal:  Cancer Lett       Date:  1999-12-01       Impact factor: 8.679

7.  Chemoprevention of familial adenomatous polyposis development in the APC(min) mouse model by 1,4-phenylene bis(methylene)selenocyanate.

Authors:  C V Rao; I Cooma; J G Rodriguez; B Simi; K El-Bayoumy; B S Reddy
Journal:  Carcinogenesis       Date:  2000-04       Impact factor: 4.944

8.  Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis.

Authors:  C H Chiu; M F McEntee; J Whelan
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

9.  A fish oil derived concentrate enriched in eicosapentaenoic and docosahexaenoic acid as ethyl ester suppresses the formation and growth of intestinal polyps in the Min mouse.

Authors:  J E Paulsen; I K Elvsaas; I L Steffensen; J Alexander
Journal:  Carcinogenesis       Date:  1997-10       Impact factor: 4.944

10.  Suppression of intestinal polyp development by low-fat and high-fiber diet in Apc(delta716) knockout mice.

Authors:  K Hioki; N Shivapurkar; H Oshima; O Alabaster; M Oshima; M M Taketo
Journal:  Carcinogenesis       Date:  1997-10       Impact factor: 4.944

View more
  80 in total

1.  A hexane fraction of American ginseng suppresses mouse colitis and associated colon cancer: anti-inflammatory and proapoptotic mechanisms.

Authors:  Deepak Poudyal; Phuong Mai Le; Tia Davis; Anne B Hofseth; Alena Chumanevich; Alexander A Chumanevich; Michael J Wargovich; Mitzi Nagarkatti; Prakash S Nagarkatti; Anthony Windust; Lorne J Hofseth
Journal:  Cancer Prev Res (Phila)       Date:  2012-01-31

2.  Therapeutic effect of orally administered microencapsulated oxaliplatin for colorectal cancer.

Authors:  Aleksandra M Urbanska; Emmanouil D Karagiannis; Gonzalo Guajardo; Robert S Langer; Daniel G Anderson
Journal:  Biomaterials       Date:  2012-04-01       Impact factor: 12.479

3.  Highly purified eicosapentaenoic acid as free fatty acids strongly suppresses polyps in Apc(Min/+) mice.

Authors:  Lucia Fini; Giulia Piazzi; Claudio Ceccarelli; Yahya Daoud; Andrea Belluzzi; Alessandra Munarini; Giulia Graziani; Vincenzo Fogliano; Michael Selgrad; Melissa Garcia; Antonio Gasbarrini; Robert M Genta; C Richard Boland; Luigi Ricciardiello
Journal:  Clin Cancer Res       Date:  2010-10-28       Impact factor: 12.531

4.  Conjugated linoleic acids differentially alter polyp number and diameter in the Apc(min/+) mouse model of intestinal cancer.

Authors:  N Mandir; R A Goodlad
Journal:  Cell Prolif       Date:  2008-04       Impact factor: 6.831

5.  Endoscopic imaging and size estimation of colorectal adenomas in the multiple intestinal neoplasia mouse.

Authors:  Harvey H Hensley; Carrie E Merkel; Wen-Chi L Chang; Karthik Devarajan; Harry S Cooper; Margie L Clapper
Journal:  Gastrointest Endosc       Date:  2009-03       Impact factor: 9.427

6.  Why animal studies are often poor predictors of human reactions to exposure.

Authors:  Michael B Bracken
Journal:  J R Soc Med       Date:  2009-03       Impact factor: 5.344

7.  Role of microRNAs in resveratrol-mediated mitigation of colitis-associated tumorigenesis in Apc(Min/+) mice.

Authors:  Ibrahim Altamemi; E Angela Murphy; James F Catroppo; Elizabeth E Zumbrun; Jiajia Zhang; Jamie L McClellan; Udai P Singh; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Pharmacol Exp Ther       Date:  2014-05-09       Impact factor: 4.030

8.  Serum nutrients and habitual dietary intake in colectomized FAP patients in Norway.

Authors:  Kari Almendingen; Olau Fausa; Arne Tore Høstmark; Jorunn Bratlie; Lars Mørkerid; Lars Aabakken; Morten Harald Vatn
Journal:  Eur J Nutr       Date:  2009-01-13       Impact factor: 5.614

9.  Silibinin suppresses spontaneous tumorigenesis in APC min/+ mouse model by modulating beta-catenin pathway.

Authors:  Subapriya Rajamanickam; Manjinder Kaur; Balaiya Velmurugan; Rana P Singh; Rajesh Agarwal
Journal:  Pharm Res       Date:  2009-09-25       Impact factor: 4.200

10.  Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development.

Authors:  Rengasamy R M Maran; Ann Thomas; Megan Roth; Zhonghua Sheng; Noriko Esterly; David Pinson; Xin Gao; Yawei Zhang; Vadivel Ganapathy; Frank J Gonzalez; Grace L Guo
Journal:  J Pharmacol Exp Ther       Date:  2008-11-03       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.